- ISIN
- US17248W1053
- CUSIP
- 17248W105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 8, 2021
Highlights
- Market Cap
- $39.41M
- Enterprise Value
- -$24.32B
- EPS (TTM)
- -$1.49K
- Gross Profit (TTM)
- $165.29K
- EBITDA (TTM)
- -$15.76M
- Year Range
- $3.16 - $11.89
- Target Price
- $11.00
- ROA (TTM)
- -30.23%
- ROE (TTM)
- -49.46%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CING Performance Chart
Cingulate Inc. (CING) is down 7.1% since the beginning of the year. At $4 per share, CING is trading 66.1% below its 52-week high of $12.
Loading charts...
Returns By Period
Cingulate Inc. (CING) has returned -7.14% so far this year and 1.26% over the past 12 months.
Cingulate Inc.
- 1D
- 11.94%
- 1M
- -24.95%
- YTD
- -7.14%
- 6M
- 3.60%
- 1Y
- 1.26%
- 3Y*
- -75.04%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
CING Monthly Returns History
Based on dividend-adjusted daily data since Dec 8, 2021, CING's average daily return is +0.04%, while the average monthly return is -5.22%.
Historically, 38% of months were positive and 62% were negative. The best month was Feb 2023 with a return of +86.3%, while the worst month was Jan 2024 at -59.5%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, CING closed higher 44% of trading days. The best single day was Aug 16, 2024 with a return of +268.5%, while the worst single day was Feb 2, 2024 at -60.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 32.26% | 9.23% | -0.96% | -17.07% | -19.22% | -3.12% | -7.14% | ||||||
| 2025 | -7.71% | -9.45% | 4.37% | -2.09% | -6.89% | 3.83% | 27.27% | -22.97% | -1.75% | -3.32% | -1.58% | 16.35% | -11.97% |
| 2024 | -59.48% | -56.61% | -18.22% | -16.62% | -23.57% | -54.35% | 10.34% | 86.21% | -36.12% | -19.84% | 7.92% | 13.07% | -94.63% |
| 2023 | -3.93% | 86.32% | -44.97% | 9.64% | -15.74% | 2.20% | -43.98% | 23.24% | 10.42% | -39.35% | -27.09% | 22.01% | -61.75% |
| 2022 | -32.97% | -22.70% | 37.76% | -17.77% | -32.72% | 33.94% | -15.75% | 34.15% | -35.15% | 0.93% | -8.08% | 0.74% | -63.77% |
| 2021 | -37.98% | -37.98% |
Benchmark Metrics
Cingulate Inc. has an annualized alpha of -2.58%, beta of 1.06, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since December 09, 2021.
- This stock participated in 54.50% of S&P 500 Index downside but only -149.94% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -2.58%
- Beta
- 1.06
- R²
- 0.01
- Upside Capture
- -149.94%
- Downside Capture
- 54.50%
Return for Risk
Risk / Return Rank
CING ranks 42 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Cingulate Inc. (CING) and compare them to S&P 500 Index.
| CING | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.01 | 2.39 | -2.37 |
Sortino ratioReturn per unit of downside risk | 0.69 | 3.25 | -2.57 |
Omega ratioGain probability vs. loss probability | 1.09 | 1.43 | -0.35 |
Calmar ratioReturn relative to maximum drawdown | 0.02 | 3.11 | -3.10 |
Martin ratioReturn relative to average drawdown | 0.04 | 14.38 | -14.34 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cingulate Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cingulate Inc. was 99.83%, occurring on Aug 14, 2024. The portfolio has not yet recovered.
The current Cingulate Inc. drawdown is 99.62%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -99.83%Aug 2024 | 2y 8mo | — | 4y 5moDec 2021 - now |
Drawdown Indicators
| CING | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.83% | -56.78% | -43.05% |
Max Drawdown (1Y)Largest decline over 1 year | -69.13% | -9.10% | -60.03% |
Max Drawdown (3Y)Largest decline over 3 years | -99.29% | -18.90% | -80.39% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.62% | 0.00% | -99.62% |
Average DrawdownAverage peak-to-trough decline | -87.56% | -10.72% | -76.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 33.17% | 1.97% | +31.20% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cingulate Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cingulate Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CING in comparison with other companies in the Biotechnology industry. Currently, CING has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CING
Add Cingulate Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CING